International Journal of
Reproductive Biomedicine
Wed, May 15, 2024
[Archive]
Volume 11, Issue 9 (12-2013)
IJRM 2013, 11(9): 761-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Binesh F, Akhavan A, Davoodi M. Does oral contraceptive pill increase the risk of abnormal Pap smear?. IJRM 2013; 11 (9) :761-0
URL: http://ijrm.ir/article-1-464-en.html
URL: http://ijrm.ir/article-1-464-en.html
1- Department of Pathology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran , Binesh44@yahoo.com
2- Department of Radiotherapy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3- Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2- Department of Radiotherapy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3- Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Abstract: (2156 Views)
Background: It is noted that oral contraceptive pills increase the risk of abnormal Pap smear but results have been inconsistent across the populations.
Objective: This study aimed to evaluate the association between oral contraceptive pill (OCP) consumption and abnormal Pap smear in women who referred to Shahid Sadoughi and Madar hospitals in Yazd.
Materials and Methods: A cross sectional descriptive study was carried out and a database of all Pap smear reports from 2009-2011 at Cytopathology Department of Shahid Sadoughi and Madar hospitals in Yazd, Iran was reviewed. A total number of 1286 women with history of OCP consumption were selected as the case group and 1218 women applying other contraceptive methods were selected as control group for evaluation. Both case and control groups were matched by age, parity and socioeconomic status. All of the women in this study maintained a single partner as their husband and none of them were considered as smokers. The duration of OCP use was at least 5 years.
Results: Abnormal Pap smear results were observed in 0.4% of cases and 0.2% of controls. There was no significant association between OCP consumption and abnormal Pap smear (p=0.727).
Conclusion: Our findings did not show any specific association between OCP consumption and abnormal Pap smear results. In addition, the number of abnormal Pap smears in women who consumed OCP was lower than that of western countries. More prospective studies are required.
Objective: This study aimed to evaluate the association between oral contraceptive pill (OCP) consumption and abnormal Pap smear in women who referred to Shahid Sadoughi and Madar hospitals in Yazd.
Materials and Methods: A cross sectional descriptive study was carried out and a database of all Pap smear reports from 2009-2011 at Cytopathology Department of Shahid Sadoughi and Madar hospitals in Yazd, Iran was reviewed. A total number of 1286 women with history of OCP consumption were selected as the case group and 1218 women applying other contraceptive methods were selected as control group for evaluation. Both case and control groups were matched by age, parity and socioeconomic status. All of the women in this study maintained a single partner as their husband and none of them were considered as smokers. The duration of OCP use was at least 5 years.
Results: Abnormal Pap smear results were observed in 0.4% of cases and 0.2% of controls. There was no significant association between OCP consumption and abnormal Pap smear (p=0.727).
Conclusion: Our findings did not show any specific association between OCP consumption and abnormal Pap smear results. In addition, the number of abnormal Pap smears in women who consumed OCP was lower than that of western countries. More prospective studies are required.
Type of Study: Original Article |
References
1. Rosai J. Ackerman's surgical pathology, female reproductive system, uterus-cervix. 10th Ed. Elsevier Mosbey; 2011: 1447-1448.
2. Farjadian S, Asadi E, Doroudchi M, Dehaghani AS, Tabei SZ, Kumar VP, et al. High risk HPV types in southern Iranian patients with cervical cancer. Pathol Oncol Res 2003; 9:121-125. [DOI:10.1007/BF03033756]
3. World Health Organization. ICO Information Center on HPV and Cervical Cancer (HPV Information Center): Human papillomavirus and related cancers. Sum Rep Update 2010.
4. Jafari Shobeiri M, Halimi M, Dastranj A, Shahamphar J. Screening for cervical cancer and precancerous lesions in Tabriz. MJIRI 2007; 21: 1-10.
5. Thomison J, Thomas LK, Shroyer KR. Human papillomavirus: molecular and cytologic/ histologic aspects related to cervical intraepithelial neoplasia and carcinoma. Hum Pathol 2008; 39: 154-166. [DOI:10.1016/j.humpath.2007.11.002]
6. Gichangi P, Estambale B, Bwayo J, Rogo K, Ojwang S, Opiyo A, et al. Knowledge and practice about cervical cancer and Pap smear testing among patients at Kenyatta National Hospital, Nairobi, Kenya. Intl J Gynecol Cancer 2003; 13: 827-833. [DOI:10.1111/j.1525-1438.2003.13612.x]
7. Jonathan S. Berek, cervical cancer, Deborah L. Berek MA, Berek and Novak's Gynecology. 15th Ed united-state of America, Lippincott Williams and Wilkins 2012; 1305.
8. Santin AD, Zhan F, Bignotti E, Siegel ER, Cané S, Bellone S, et al. Gene expression profiles of primary HPV16-and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 2005; 331: 269-291. [DOI:10.1016/j.virol.2004.09.045]
9. Sohail R, Nazir R, Latif Y, Zaman F. Evaluation of cervical smear in women attending gynecological OPD. J Surg Pak (Int) 2008; 13: 3.
10. Sohail R, Nazir R, Latif Y, Zaman F. Evaluation of cervical smear in women attending gynecological OPD. J Surg Pakn (Int) 2008; 13: 121-123.
11. Kiatiyosnusorn R, Suprasert P, Srisomboon J, Siriaree S, Khunamornpong S, Kietpeerakool, C. High-grade histologic lesions in women with low-grade squamous intraepithelial lesion cytology from a region of Thailand with a high incidence of cervical cancer. Int J Gynaecol Obstet 2010; 110: 133-136. [DOI:10.1016/j.ijgo.2010.03.022]
12. Marshall K. Cervical dysplasia: early intervention. Altern Med Rev 2003; 8: 156-170.
13. Edlow AG, Bartz D. Hormonal contraceptive options for women with headache: A review of the evidence. Rev Obstet Gynecol 2010; 3: 55-65.
14. Saadatnia M, Naghavi N, Fatehi F, Zare M, Tajmirriahi M. Oral contraceptive misuse as a risk factor for cerebral venous and sinus thrombosis. J Res Med Sci 2012; 17: 344-347.
15. Ye Z, Thomas DB, Ray RM. Combined oral contraceptives and risk of cervical carcinoma in situ. Int J Epidemiol 1995; 24: 19-26. [DOI:10.1093/ije/24.1.19]
16. Mafuva C, Djarova T, Matarira HT. Influence of combined oral contraceptives on the onset of cervical intraepithelial neoplasia. Afr J Health Sci 2002; 9: 129-137.
17. McFarlane-Anderson N, Patience E, Bazuaye M, Jackson D, Monica S, Horace M Fletcher, Cervical dysplasia and cancer and the use of hormonal contraceptives in Jamaican women. BMC Womens Health 2008; 8: 9. [DOI:10.1186/1472-6874-8-9]
18. Molina R, Thomas DB, Dabancens A, Lopez J, Ray RM, Martinez L, et al. Oral contraceptives and cervical carcinoma in situ in Chile. Cancer Res 1988; 48: 1011-1015.
19. Sayednozadi S, Hassany M, Ramezani MA. Association of oral contraceptives and abnormal Pap smear. Am J Appl Sci 2005; 2: 1150-1152. [DOI:10.3844/ajassp.2005.1150.1152]
20. Becker TM, Wheeler CM, McGOUGH NS, Stidley CA, Parmenter CA, Dorin MH, et al. Contraceptive and reproductive risks for cervical dysplasia in southwestern Hispanic and non-Hispanic white women. Int J Epidemiol 1994; 23: 913-922. [DOI:10.1093/ije/23.5.913]
21. Nygård J, Skare G, Thoresen SØ. The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen 2002; 9: 86-91. [DOI:10.1136/jms.9.2.86]
22. Berry G, Maclennan R, Shearman R, Jelihovsky T, Booth JC, Molina R, et al. Invasive squamous‐cell cervical carcinoma and combined oral contraceptives: Results from a multinational study. Int J Cancer 1993; 55: 228-236. [DOI:10.1002/ijc.2910550211]
23. Herrero R, Brinton LA, Reeves WC, Brenes MM, De Britton RC, Tenorio F, et al. Injectable contraceptives and risk of invasive cervical cancer: evidence of an association. Int J Cancer 2006; 46: 5-7. [DOI:10.1002/ijc.2910460103]
24. Brinton LA. Oral contraceptives and cervical neoplasia. Contraception 1991; 43: 581-595. [DOI:10.1016/0010-7824(91)90005-Z]
25. Solomon D, Nayar R. The Bethesda System for reporting cervical cytology: definitions, criteria, and explanatory notes: Springer; 2004. [DOI:10.1007/978-1-4612-2042-8]
26. Celentano DD, Klassen A, Weisman CS, Rosenshein NB. The role of contraceptive use in cervical cancer: the Maryland cervical cancer case-control study. Am J Epidemiol 1987; 126: 592-604. [DOI:10.1093/oxfordjournals.aje.a114699]
27. Dallenbach-Hellweg G. On the origin and histological structure of adenocarcinoma of the endocervix in women under 50 years of age. Pathol Res Prac 1984; 179: 38-50. [DOI:10.1016/S0344-0338(84)80059-X]
28. Marc A, Fritz, Leon S peroff, Oral contraception, Marc A. Fritz, Leon Speroff, Clinical gynecologic endocrinology and infertility. 8th Ed. United State of America, Lippincott Williams and Wilkins; 2011: 996-997.
29. Green J, De Gonzalez AB, Smith J, Franceschi S, Appleby P, Plummer M, et al. Human papillomavirus infection and use of oral contraceptives. Br J Cancer 2003; 88: 1713-1720. [DOI:10.1038/sj.bjc.6600971]
30. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F [DOI:10.1002/(SICI)1096-9896(199909)189:13.0.CO;2-F]
31. Hausen HZ. Human genital cancer: Synergism between two virus infections or synergism between a virus infection and initiating events? Lancet 1982; 320: 1370-1372. [DOI:10.1016/S0140-6736(82)91273-9]
32. Negrini BP, Schiffman MH, Kurman RJ, Barnes W, Lannom L, Malley K, et al. Oral contraceptive use, human papillomavirus infection, and risk of early cytological abnormalities of the cervix. Cancer Res 1990; 50: 4670-4675.
33. Gayed M, Bernatsky S, Ramsey-Goldman R, Clarke A, Gordon C. Lupus and cancer. Lupus 2009; 18: 479-485. [DOI:10.1177/0961203309102556]
34. Smith JS, Green J, de Gonzalez AB, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361: 1159-1167. [DOI:10.1016/S0140-6736(03)12949-2]
35. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2008; 50: 7-33. [DOI:10.3322/canjclin.50.1.7]
36. Mosavi-Jarrahi A, Mohagheghi M, Zeraatti H, Mortazavi H. Cancer registration in Iran. Asian Pac J Cancer Prev 2001; 2: 25-29.
37. Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol 1995; 85: 793-801. [DOI:10.1016/0029-7844(95)00022-J]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
